المؤلفون: Hickman A; Department of Melanoma Medical Oncology., Koetsier J; Department of Melanoma Medical Oncology., Kurtanich T; Department of Melanoma Medical Oncology., Nielsen MC; Department of Melanoma Medical Oncology., Winn G; Department of Melanoma Medical Oncology., Wang Y; Department of Melanoma Medical Oncology., Bentebibel SE; Department of Melanoma Medical Oncology., Shi L; Department of Melanoma Medical Oncology., Punt S; Department of Melanoma Medical Oncology., Williams L; Department of Melanoma Medical Oncology., Haymaker C; Department of Translational Molecular Pathology, and., Chesson CB; Department of Melanoma Medical Oncology., Fa'ak F; Department of Melanoma Medical Oncology., Dominguez AL; Department of Melanoma Medical Oncology., Jones R; Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kuiatse I; Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Caivano AR; Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas, USA., Khounlo S; Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas, USA., Warier ND; Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas, USA., Marathi U; 7 Hills Pharma, Houston, Texas, USA., Market RV; Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas, USA., Biediger RJ; Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas, USA., Craft JW Jr; Department of Biology and Chemistry, University of Houston, Houston, Texas, USA., Hwu P; Department of Melanoma Medical Oncology., Davies MA; Department of Melanoma Medical Oncology., Woodside DG; Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas, USA., Vanderslice P; Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas, USA., Diab A; Department of Melanoma Medical Oncology., Overwijk WW; Department of Melanoma Medical Oncology., Hailemichael Y; Department of Melanoma Medical Oncology.

المصدر: The Journal of clinical investigation [J Clin Invest] 2022 Jul 01; Vol. 132 (13).

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

مواضيع طبية MeSH: Lymphocyte Function-Associated Antigen-1*/genetics , Lymphocyte Function-Associated Antigen-1*/metabolism , Melanoma*/drug therapy , Melanoma*/genetics, CD8-Positive T-Lymphocytes ; CTLA-4 Antigen ; Humans ; Immunotherapy/methods ; Lymphocytes, Tumor-Infiltrating ; Programmed Cell Death 1 Receptor ; T-Lymphocytes/metabolism ; Tumor Microenvironment

المؤلفون: Hailemichael Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnson DH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Precision Cancer Therapies Program, Department of Hematology and Medical Oncology, Ochsner Health, New Orleans, LA, USA., Abdel-Wahab N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Rheumatology and Rehabilitation, Assiut University Hospitals, Faculty of Medicine, Assiut University, Egypt., Foo WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daher M; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Saberian C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ogata D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim ST; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nurieva R; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Abu-Sbeih H; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fa'ak F; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mathew A; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Y; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Falohun A; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Trinh V; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zobniw C; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Spillson C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burks JK; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Awiwi M; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elsayes K; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soto LS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melendez BD; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Curry J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lizee G; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Singh S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ekmekcioglu S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: adiab@mdanderson.org.

المصدر: Cancer cell [Cancer Cell] 2022 May 09; Vol. 40 (5), pp. 509-523.e6. Date of Electronic Publication: 2022 May 09.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

مواضيع طبية MeSH: Colitis*/chemically induced , Neoplasms*/drug therapy, Animals ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy ; Interleukin-6 ; Mice ; Myeloid Cells

المؤلفون: Federico L; Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, USA., McGrail DJ; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Ravelli A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Karpinets T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Jiang P; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Reuben A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Negrao MV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Li J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Khairullah R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Weissferdt A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Vaporciyan AA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Antonoff MB; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Walsh G; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Lin SY; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Wistuba I; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Roth J; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Byers LA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Gaudreau PO; Department of Oncology, Queens' University and the Canadian Cancer Trials Group, Kingston, Canada., Uraoka N; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Cruz AF; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Dejima H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Lazcano RN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Solis LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Swisher S; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jzhang20@mdanderson.org., Sepesi B; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: bsepesi@mdanderson.org., Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: dlgibbon@mdanderson.org., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: cbernatchez@mdanderson.org.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Jan; Vol. 33 (1), pp. 42-56. Date of Electronic Publication: 2021 Oct 13.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/pathology, CD8-Positive T-Lymphocytes ; Humans ; Lymphocytes, Tumor-Infiltrating/pathology ; Prognosis

المؤلفون: Horiuchi S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA., Wu H; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Liu WC; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Biomedical Translation Research Center, Academia Sinica, Taipei 11571, Taiwan., Schmitt N; Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA.; ImmunoConcEpT, CNRS UMR 5164, Bordeaux University, Bordeaux 33076, France., Provot J; Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA., Liu Y; Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA., Bentebibel SE; Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA., Albrecht RA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Schotsaert M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Forst CV; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Zhang B; Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Ueno H; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX 75204, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Department of Immunology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.; Institute for the Advanced Study of Human Biology, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.

المصدر: Science advances [Sci Adv] 2021 Oct 08; Vol. 7 (41), pp. eabj1249. Date of Electronic Publication: 2021 Oct 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Sahaf B; Stanford Cancer Institute, Stanford Medicine, Stanford University, California. bsahaf@stanford.edu., Pichavant M; Stanford Institute for Immunity, Transplantation and Infection, Stanford Medicine, Stanford university, California., Lee BH; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York., Duault C; Stanford Institute for Immunity, Transplantation and Infection, Stanford Medicine, Stanford university, California., Thrash EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Davila M; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York., Fernandez N; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York., Millerchip K; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sigal N; Stanford Institute for Immunity, Transplantation and Infection, Stanford Medicine, Stanford university, California., Del Valle DM; Human Immune Monitoring Center, Tisch Cancer Institute and the Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Ranasinghe S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Fayle S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sanchez-Espiridion B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Harvard University, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kim-Schulze S; Human Immune Monitoring Center, Tisch Cancer Institute and the Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Gnjatic S; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York., Bendall SC; Department of Pathology, Stanford Medicine, Stanford University, Stanford, California., Song M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Thurin M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maecker HT; Stanford Institute for Immunity, Transplantation and Infection, Stanford Medicine, Stanford university, California., Rahman A; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Sep 15; Vol. 27 (18), pp. 5062-5071. Date of Electronic Publication: 2021 Jul 15.

نوع المنشور: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Flow Cytometry* , Leukocytes, Mononuclear*, Biomarkers, Tumor/*analysis , Neoplasms/*blood , Neoplasms/*immunology , Neoplasms/*pathology, Humans ; Monitoring, Immunologic

المؤلفون: Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Johnson DH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Murthy R; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Uemura MI; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hudgens CW; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Safa H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., James M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Andtbacka RHI; Surgical Oncology Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Johnson DB; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Shaheen M; Department of Medicine and Cancer Center, University of Arizona, Tucson, Arizona., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rahimian S; Idera Pharmaceuticals, Inc., Exton, Pennsylvania., Chunduru SK; Idera Pharmaceuticals, Inc., Exton, Pennsylvania., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tetzlaff MT; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Overwijk WW; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gabrail N; Department of Oncology, Gabrail Cancer Center, Canton, Ohio., Agrawal S; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts., Doolittle G; Department of Oncology, University of Kansas Medical Center, Kansas City, Kansas., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Markowitz J; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. adiab@mdanderson.org cbernatchez@mdanderson.org., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. adiab@mdanderson.org cbernatchez@mdanderson.org.

المصدر: Cancer discovery [Cancer Discov] 2021 Aug; Vol. 11 (8), pp. 1996-2013. Date of Electronic Publication: 2021 Mar 11.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Immune Checkpoint Inhibitors*/administration & dosage , Immune Checkpoint Inhibitors*/therapeutic use , Ipilimumab*/administration & dosage , Ipilimumab*/therapeutic use , Melanoma*/drug therapy , Skin Neoplasms*/drug therapy, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols ; Treatment Outcome ; United States

المؤلفون: Bentebibel SE; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. Sbentebibel@mdanderson.org., Diab A; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. Adiab@mdanderson.org.

المصدر: Current oncology reports [Curr Oncol Rep] 2021 May 18; Vol. 23 (7), pp. 83. Date of Electronic Publication: 2021 May 18.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE

مواضيع طبية MeSH: Cytokines/*therapeutic use , Melanoma/*drug therapy, Cytokines/adverse effects ; Cytokines/pharmacokinetics ; Cytokines/physiology ; Humans ; Interferon-alpha/therapeutic use ; Interleukin-10/therapeutic use ; Interleukin-15/therapeutic use ; Interleukin-2/therapeutic use

المؤلفون: Diab A; The University of Texas MD Anderson Cancer Center, Houston, Texas. adiab@mdanderson.org., Tannir NM; The University of Texas MD Anderson Cancer Center, Houston, Texas., Bentebibel SE; The University of Texas MD Anderson Cancer Center, Houston, Texas., Hwu P; The University of Texas MD Anderson Cancer Center, Houston, Texas., Papadimitrakopoulou V; The University of Texas MD Anderson Cancer Center, Houston, Texas., Haymaker C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Kluger HM; Yale School of Medicine, New Haven, Connecticut., Gettinger SN; Yale School of Medicine, New Haven, Connecticut., Sznol M; Yale School of Medicine, New Haven, Connecticut., Tykodi SS; University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington., Curti BD; Providence Cancer Center and Earle A. Chiles Research Institute, Portland, Oregon., Tagliaferri MA; Nektar Therapeutics, San Francisco, California., Zalevsky J; Nektar Therapeutics, San Francisco, California., Hannah AL; Nektar Therapeutics, San Francisco, California., Hoch U; Nektar Therapeutics, San Francisco, California., Aung S; Nektar Therapeutics, San Francisco, California., Fanton C; Nektar Therapeutics, San Francisco, California., Rizwan A; Nektar Therapeutics, San Francisco, California., Iacucci E; Nektar Therapeutics, San Francisco, California., Liao Y; Nektar Therapeutics, San Francisco, California., Bernatchez C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Hurwitz ME; Yale School of Medicine, New Haven, Connecticut., Cho DC; Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York.

المصدر: Cancer discovery [Cancer Discov] 2020 Aug; Vol. 10 (8), pp. 1158-1173. Date of Electronic Publication: 2020 May 21.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Carcinoma, Non-Small-Cell Lung/*drug therapy , Carcinoma, Renal Cell/*drug therapy , Immune Checkpoint Inhibitors/*administration & dosage , Interleukin-2/*analogs & derivatives , Kidney Neoplasms/*drug therapy , Lung Neoplasms/*drug therapy , Melanoma/*drug therapy , Nivolumab/*administration & dosage , Polyethylene Glycols/*administration & dosage, Adult ; Aged ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/immunology ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immunotherapy ; Interleukin-2/administration & dosage ; Interleukin-2/adverse effects ; Kidney Neoplasms/genetics ; Kidney Neoplasms/immunology ; Lung Neoplasms/genetics ; Lung Neoplasms/immunology ; Lymphocyte Count ; Lymphocytes, Tumor-Infiltrating/drug effects ; Lymphocytes, Tumor-Infiltrating/immunology ; Male ; Melanoma/genetics ; Melanoma/immunology ; Middle Aged ; Nivolumab/adverse effects ; Polyethylene Glycols/adverse effects ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Treatment Outcome ; Young Adult

المؤلفون: Sharma M; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khong H; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fa'ak F; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bentebibel SE; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Janssen LME; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chesson BC; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Creasy CA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Forget MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kahn LMS; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pazdrak B; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karki B; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hailemichael Y; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Singh M; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vianden C; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vennam S; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Bharadwaj U; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA., Tweardy DJ; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA., Haymaker C; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bernatchez C; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang S; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Dan L. Duncan Cancer Center, Houston, TX, USA., Rajapakshe K; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Hurwitz ME; Yale Comprehensive Cancer Center, New Haven, CT, USA., Sznol M; Yale University Cancer Center, Yale University, New Haven, CT, USA., Hwu P; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hoch U; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Addepalli M; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Charych DH; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Zalevsky J; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Diab A; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Overwijk WW; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com.; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA. woverwijk@nektar.com.; The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA. woverwijk@nektar.com.; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com.

المصدر: Nature communications [Nat Commun] 2020 Jan 31; Vol. 11 (1), pp. 661. Date of Electronic Publication: 2020 Jan 31.

نوع المنشور: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell/*drug therapy , Interleukin-2/*analogs & derivatives , Melanoma/*drug therapy , Polyethylene Glycols/*administration & dosage , Prodrugs/*administration & dosage , T-Lymphocytes, Regulatory/*immunology, Animals ; Antibodies, Monoclonal, Humanized/administration & dosage ; CD8-Positive T-Lymphocytes/immunology ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/immunology ; Cohort Studies ; Drug Therapy, Combination ; Female ; Humans ; Interferon-gamma/genetics ; Interferon-gamma/immunology ; Interleukin-2/administration & dosage ; Interleukin-2/agonists ; Interleukin-2/immunology ; Ipilimumab/administration & dosage ; Lymphocyte Activation/drug effects ; Melanoma/genetics ; Melanoma/immunology ; Mice ; Mice, Inbred C57BL ; Receptors, Interleukin-2/genetics ; Receptors, Interleukin-2/immunology ; Tumor Necrosis Factor-alpha/genetics ; Tumor Necrosis Factor-alpha/immunology

المؤلفون: Bentebibel SE; The University of Texas MD Anderson Cancer Center, Houston, Texas., Hurwitz ME; Yale School of Medicine, New Haven, Connecticut., Bernatchez C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Haymaker C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Hudgens CW; The University of Texas MD Anderson Cancer Center, Houston, Texas., Kluger HM; Yale School of Medicine, New Haven, Connecticut., Tetzlaff MT; The University of Texas MD Anderson Cancer Center, Houston, Texas., Tagliaferri MA; Nektar Therapeutics, San Francisco, California., Zalevsky J; Nektar Therapeutics, San Francisco, California., Hoch U; Nektar Therapeutics, San Francisco, California., Fanton C; Nektar Therapeutics, San Francisco, California., Aung S; Nektar Therapeutics, San Francisco, California., Hwu P; The University of Texas MD Anderson Cancer Center, Houston, Texas., Curti BD; Providence Cancer Institute and Earle A. Chiles Research Institute, Portland, Oregon., Tannir NM; The University of Texas MD Anderson Cancer Center, Houston, Texas., Sznol M; Yale School of Medicine, New Haven, Connecticut., Diab A; The University of Texas MD Anderson Cancer Center, Houston, Texas. adiab@mdanderson.org.

المصدر: Cancer discovery [Cancer Discov] 2019 Jun; Vol. 9 (6), pp. 711-721. Date of Electronic Publication: 2019 Apr 15.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Interleukin-2/*analogs & derivatives , Interleukin-2/*metabolism , Interleukin-2 Receptor alpha Subunit/*metabolism , Neoplasms/*drug therapy , Neoplasms/*metabolism , Polyethylene Glycols/*therapeutic use , Signal Transduction/*drug effects, Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Biomarkers ; CD8-Positive T-Lymphocytes ; Cell Line, Tumor ; Humans ; Interleukin-2/administration & dosage ; Interleukin-2/adverse effects ; Interleukin-2/pharmacokinetics ; Interleukin-2/therapeutic use ; Neoplasms/etiology ; Neoplasms/pathology ; Polyethylene Glycols/administration & dosage ; Polyethylene Glycols/adverse effects ; Polyethylene Glycols/pharmacokinetics ; Treatment Outcome ; Tumor Microenvironment/drug effects